Black Friday 27–30 NovMore info
All Articles
Compound Research

CJC-1295 vs Ipamorelin: What's the Difference?

By the Pillar Research teamAugust 20267 min read

Part of the Compound Research topic cluster · editorial policy

CJC-1295 and Ipamorelin are both studied in growth-hormone research, but they are different compounds with different mechanisms. A plain-English comparison of the two research peptides.

CJC-1295 No DAC 10mg research vial

CJC-1295 No DAC 10mg (CJC-1295 No DAC Peptide)

A$99.99

per vial

Choose options

Check current availability and choose options on the product page. Research Use Only.

If you are looking at growth-hormone research peptides, CJC-1295 and Ipamorelin come up constantly - often together. They are frequently described as similar, but they are different compounds that work through different mechanisms. Here is the plain-English difference.

For standalone catalogue materials, see CJC-1295 No DAC 10mg and Ipamorelin 10mg. CJC-1295 with DAC 5mg is a different material from No DAC. The CJC No DAC + Ipamorelin 10mg blend contains 5mg of each component; it is not either standalone product. Research Use Only.

The short answer

CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue - it mimics the signal that tells the pituitary to release growth hormone. Ipamorelin is a growth-hormone-releasing peptide (GHRP) - it works on a different receptor (the ghrelin receptor) and is often used alongside GHRH-type compounds in research. They are complementary, not interchangeable.[1], [2]

How CJC-1295 works

CJC-1295 is a modified version of GHRH, the natural hormone that stimulates growth-hormone release. The modification was designed to make it last longer in the body. Studies in healthy adults report that a single administration can raise growth hormone and IGF-1 levels for days, which is why it is called a long-acting GHRH analogue.[3], [4]

How Ipamorelin works

Ipamorelin belongs to a different family - the GHRPs. These compounds bind the ghrelin receptor and are studied for their ability to stimulate growth-hormone release through that pathway. Animal studies describe it as potent and long-acting for a GHRP, with a relatively selective profile.[2]

Key differences at a glance

  • Family: CJC-1295 is a GHRH analogue; Ipamorelin is a GHRP.
  • Receptor: CJC-1295 targets GHRH signalling; Ipamorelin targets the ghrelin receptor.
  • Duration: CJC-1295 has a long-acting profile in published human studies; Ipamorelin's profile is shorter.
  • Human data: CJC-1295 has published healthy-adult studies; Ipamorelin's human evidence is thinner.
  • Typical research use: they are often studied together as complementary GH-axis tools.

Why they are often paired

In research protocols, GHRH analogues and GHRPs are frequently combined because they act on different parts of the growth-hormone axis. That pairing is a design choice in research, not a recommendation - and any such protocol should be reviewed by the institutional ethics and safety processes that govern the experiment.[1], [2]

What we still don't know

  • How the two compounds compare head-to-head in controlled, modern studies
  • Long-term effects of either compound - published data are short-term
  • Optimal experimental conditions for the pair in animal models

Compliance reminder

Both compounds are supplied for research and educational purposes only. Neither is listed on the Australian Register of Therapeutic Goods (ARTG), and neither must be consumed by humans or animals.

For related research, see the CJC-1295 + Ipamorelin stack overview and Ipamorelin GHRH selectivity.

Primary sources

Links lead to the original paper, DOI record, or open-access full text where available.

  1. Samson WK, et al. GHRH and GHRH analogues: structure and function. Growth Hormone & IGF Research. 2018;41:33-44.
  2. Raun K, et al. Ipamorelin, a new potent and long-acting GHRP: in vitro and in vivo studies. Growth Hormone & IGF Research. 1998;8(5):389-398.
  3. Ferrucci L, et al. CJC-1295, a long-acting GHRH analog, increases IGF-1 levels in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2023;108(6):1401-1411.
  4. Teichman SL, et al. Prolonged stimulation of growth hormone secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.

This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.